Arnon Shahar

Tel Aviv, TA 68125, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Common Bacterial Infections during the 3-Month Period after SARS-CoV-2 Infection: A Retrospective Cohort Study.

Common Bacterial Infections during the 3-Month Period after SARS-CoV-2 Infection: A Retrospective Cohort Study.

Journal: Healthcare (Basel, Switzerland)
Published: September 15, 2023

Use of prescription opioids in Israel and socio-economic correlations between 2010 and 2020.

Use of prescription opioids in Israel and socio-economic correlations between 2010 and 2020.

Journal: Israel journal of health policy research
Published: August 11, 2023

Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study.

Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study.

Journal: BMJ open
Published: February 22, 2023

Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.

Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.

Journal: Biomedicines
Published: February 06, 2023

Smoking cessation - better together: A retrospective cohort study.

Smoking cessation - better together: A retrospective cohort study.

Journal: Tobacco induced diseases
Published: February 06, 2023

Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.

Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.

Journal: Vaccine
Published: January 31, 2023

Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.

Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 20, 2022

Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.

Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.

Journal: Vaccine
Published: March 12, 2022

How compassionate use enabled Israel to deliver the Pfizer-BioNTech COVID-19 vaccination to vulnerable children aged 12-15 years before regulatory approval.

How compassionate use enabled Israel to deliver the Pfizer-BioNTech COVID-19 vaccination to vulnerable children aged 12-15 years before regulatory approval.

Journal: Acta paediatrica (Oslo, Norway : 1992)
Published: October 11, 2021
Showing 1-9 of 9

Last Updated: 09/26/2026